Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara

New Indication: Trastuzumab deruxtecan for her2+ NSCLC

New Indication: Trastuzumab deruxtecan for her2+ NSCLC
  • Multicenter, international, phase 2 study
  • Metastatic HER2-mutant NSCLC (refractory to standard treatment)
  • Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight
  • ORR: 55% (95% CI, 44 to 65)
  • Median DOR: 9.3 months (95% CI, 5.7 to 14.7)
  • Median PFS: 8.2 months (95% CI, 6.0 to 11.9)
  • Median OS:17.8 months (95% CI, 13.8 to 22.1).
  • Grade >=3 AEs: 46%, neutropenia 19%
  • Drug-related interstitial lung disease: 26% => 2 death

N Engl J Med. 2022; 386:241-251

Li BT, et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Reviewed by Hasan Cagri Yildirim, MD on Sep 30, 2021

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More